Boehringer jumps on KRAS cancer drug bandwagon with MD AndersonBoehringer Ingelheim has become the latest pharma company to investigate KRAS as a potential target for cancer drugs, Share XBoehringer jumps on KRAS cancer drug bandwagon with MD Andersonhttps://pharmaphorum.com/news/boehringer-jumps-on-kras-cancer-drug-bandwagon-with-md-anderson/
Three years after approval, court blocks US launch of Enbrel biosimilarSandoz is to appeal a court decision preventing it from launching a cheaper biosimilar competitor to Amgen’s Enbrel Share XThree years after approval, court blocks US launch of Enbrel biosimilarhttps://pharmaphorum.com/news/three-years-after-approval-court-blocks-us-launch-of-enbrel-biosimilar/
Cancer update buoys Amgen despite Q2 sales fallAmgen’s second quarter revenues were down 3% as competition pegged back its off-patent drugs Sensipar and Neulasta, but Share XCancer update buoys Amgen despite Q2 sales fallhttps://pharmaphorum.com/news/cancer-update-buoys-amgen-despite-q2-sales-fall/
Roche under pressure in US as Amgen/Allergan launch US cancer biosimilarsAmgen and Allergan have launched their cut-price biosimilar competitors to two big-selling cancer drugs from Roche in the Share XRoche under pressure in US as Amgen/Allergan launch US cancer biosimilarshttps://pharmaphorum.com/news/roche-under-pressure-in-us-as-amgen-allergan-launch-us-cancer-biosimilars/
German court blocks Sanofi’s cholesterol drug after Amgen lawsuitAmgen has lived up to its litigious reputation after it successfully persuaded a German court to uphold a Share XGerman court blocks Sanofi’s cholesterol drug after Amgen lawsuithttps://pharmaphorum.com/news/german-court-blocks-sanofis-cholesterol-drug-after-amgen-lawsuit/
Novartis and Amgen axe BACE drug for Alzheimer’sAnother Alzheimer’s disease drug has been axed after Novartis, Amgen and the Banner Alzheimer’s Institute decided to end Share XNovartis and Amgen axe BACE drug for Alzheimer’shttps://pharmaphorum.com/news/novartis-and-amgen-axe-bace-drug-for-alzheimers/
CHMP says no to Amgen’s osteoporosis drug EvenityAmgen and UCB have suffered another setback as they try to build momentum for Evenity, their new antibody Share XCHMP says no to Amgen’s osteoporosis drug Evenityhttps://pharmaphorum.com/news/chmp-says-no-to-amgens-osteoporosis-drug-evenity/
Three drugmakers challenge Trump’s price disclosure rulingAmgen, Merck & Co and Eli Lilly have launched a legal challenge to a new rule that will Share XThree drugmakers challenge Trump’s price disclosure rulinghttps://pharmaphorum.com/news/three-drugmakers-challenge-trumps-price-disclosure-ruling/
FDA approves Herceptin biosimilar as US patent expiresThe FDA has approved Amgen and Allergan’s biosimilar of Roche’s Herceptin, just in time for the breast cancer Share XFDA approves Herceptin biosimilar as US patent expireshttps://pharmaphorum.com/news/fda-approves-herceptin-biosimilar-as-us-patent-expires/
